A phase I/II multi-center study of Troxatyl™ in patients with refractory chronic lymphocytic leukemia (CLL), lymphoma or multiple myeloma (MM).

被引：0
|
作者：
Giles, F
Belanger, R
Toor, A
McLaughlin, P
Fayad, L
Beran, M
Albitar, M
Vose, J
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Hop Maison Neuve Rosemont, Res Ctr, Montreal, PQ H1T 2M4, Canada
[3] Univ Arkansas Med Sci, Myeloma & Transplantat Ctr, Little Rock, AR 72205 USA
[4] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Univ Nebraska, Med Ctr, Lincoln, NE 68583 USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4902
引用
收藏
页码：289B / 289B
页数：1
相关论文
共 50 条
  • [21] Correlation of systemic and mucosal immunoglobulin (Ig) levels in patients (pts) with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).
    Morrison, VA
    Opstad, NL
    Janoff, EN
    CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) : 92 - 92
  • [22] Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
    Maria Winqvist
    Fariba Mozaffari
    Marzia Palma
    Sandra Eketorp Sylvan
    Lotta Hansson
    Håkan Mellstedt
    Anders Österborg
    Jeanette Lundin
    Cancer Immunology, Immunotherapy, 2017, 66 : 91 - 102
  • [23] Common clonal tumor origin in a patient with concomitant chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).
    Sucker, C
    Kramer, A
    Bethauser, H
    Atzberger, A
    Goldschmidt, H
    Moos, M
    BLOOD, 1995, 86 (10) : 3362 - 3362
  • [24] Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration
    Stephens, Deborah M.
    Boucher, Ken
    Kander, Elizabeth
    Parikh, Sameer A.
    Parry, Erin
    Shadman, Mazyar
    Pagel, John M.
    Cooperrider, Jennifer
    Rhodes, Joanna
    Mato, Anthony R.
    Winter, Allison M.
    Hill, Brian T.
    Gaballa, Sameh
    Danilov, Alexey V.
    Phillips, Tycel J.
    Brander, Danielle M.
    Smith, Sonali M.
    Davids, Matthew S.
    Rogers, Kerry A.
    Glenn, Martha
    Byrd, John C.
    BLOOD, 2018, 132
  • [25] A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
    Shah, Jatin J.
    Stadtmauer, Edward A.
    Abonour, Rafat
    Cohen, Adam D.
    Bensinger, William I.
    Gasparetto, Cristina
    Kaufman, Jonathan L.
    Lentzsch, Suzanne
    Vogl, Dan T.
    Orlowski, Robert Z.
    Kim, Erica L.
    McKinley, Marti B.
    Durie, Brian G. M.
    BLOOD, 2012, 120 (21)
  • [26] Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration
    Stephens, Deborah M.
    Boucher, Ken
    Kander, Elizabeth
    Parikh, Sameer A.
    Parry, Erin M.
    Shadman, Mazyar
    Pagel, John M.
    Cooperrider, Jennifer
    Rhodes, Joanna
    Mato, Anthony
    Winter, Allison
    Hill, Brian
    Gaballa, Sameh
    Danilov, Alexey
    Phillips, Tycel
    Brander, Danielle M.
    Smith, Sonali M.
    Davids, Matthew
    Rogers, Kerry
    Glenn, Martha J.
    Byrd, John C.
    HAEMATOLOGICA, 2021, 106 (11) : 2845 - 2852
  • [27] Phase II trial of the diphtheria fusion protein ONTAK in patients with fludarabine refractory chronic lymphocytic leukemia (CLL).
    Frankel, AE
    Patrick, CL
    Powell, BL
    BLOOD, 2001, 98 (11) : 289B - 289B
  • [28] Results of a phase I trial of the proteasome inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).
    Woyach, Jennifer Ann
    Flynn, Joseph M.
    Jones, Jeffrey Alan
    Andritsos, Leslie A.
    Lucas, Margaret
    Chase, Weihong
    Yang, Ying
    Lucas, David M.
    Sass, Ellen
    Waymer, Sharon
    Ling, Yonghua
    Jiang, Yao
    Phelps, Mitch A.
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Phase I/II study of thrice weekly rituximab in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): A feasible and active regimen.
    Byrd, JC
    Grever, MR
    Davis, B
    Lucas, MS
    Park, K
    Goodrich, A
    Morrison, C
    Murphy, T
    Kunkel, L
    Grillo-Lopez, A
    Waselenko, JK
    Flinn, IW
    BLOOD, 1999, 94 (10) : 704A - 705A
  • [30] Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
    Winqvist, Maria
    Mozaffari, Fariba
    Palma, Marzia
    Sylvan, Sandra Eketorp
    Hansson, Lotta
    Mellstedt, Hakan
    Osterborg, Anders
    Lundin, Jeanette
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (01) : 91 - 102
12345